Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Normal-dose versus higher-dose acetylcysteine for paracetamol overdose
ISRCTN17516192Phase 2Active, not recruiting
- Sponsor
- Accord Healthcare
- Start
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of acetylcysteine in acetaminophen poisoning, sponsored by Accord Healthcare. Primary endpoint: Circulating glutathione-derived paracetamol metabolite percentage at end of infusion. Started Feb 2024; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
acetaminophen poisoning
Beyond the preview
Go deeper on ISRCTN17516192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17516192.